Thrombocytopenia induced by glycoprotein (GP) IIb-IIIa antagonists: about two cases

被引:5
作者
Abdeladim, Salma [1 ]
Elharras, Mahassine [1 ]
Elouarradi, Amal [1 ]
Bensahi, Ilham [1 ]
Oualim, Sara [1 ]
Merzouk, Fatimazahra [1 ]
Sabry, Mohamed [1 ]
机构
[1] Mohammed VI Univ Hlth Sci UM6SS, Cheick Khalifa Int Univ Hosp, Dept Cardiol, Casablanca, Morocco
关键词
Glycoprotein IIb/IIIa receptor antagonist; thrombocytopenia; tirofiban; case report; IIB/IIIA RECEPTOR; UNSTABLE ANGINA; TIROFIBAN; ABCIXIMAB; ANTIBODIES; INHIBITORS;
D O I
10.11604/pamj.2021.38.9.27215
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
In this paper, we report two cases of induced thrombocytopenia after the infusion of glycoprotein (GP) IIb/IIIa receptors antagonists, following a coronary angioplasty. The first patient is a 65-yearold woman, admitted with acute coronary syndrome requiring percutaneous angioplasty with stenting. The patient was given tirofiban + unfractionated heparin (UFH). Ten hours later, the patient revealed very severe thrombocytopenia and went into hemorrhagic shock (hematemesis and hematoma at the injection site). The patient was transfused with nine units of red blood cells (RBCs), 24 platelets pellets and 4 units of fresh frozen plasma (FFP). The second patient is a 76-year-old woman. She was admitted to hospital for acute coronary syndrome necessitating percutaneous angioplasty with stenting and a glycoprotein IIb/IIIa receptor antagonists, tirofiban + unfractionated (UFH). Four hours later, the patient presented with gingivorrhagia associated thrombocytopenia. She received six platelet pellets transfusion with well clinical and biological improvement. These two observations raise the significance of a close monitoring of platelet count after the initiation of GP IIb/IIIa antagonists infusion, which are sometimes responsible for life-threatening adverse events.
引用
收藏
页码:1 / 5
页数:5
相关论文
共 15 条
[1]   Thrombocytopenia associated with the use of GPIIb/IIIa inhibitors: position paper of the ISTH working group on thrombocytopenia and GPIIb/IIIa inhibitors [J].
Aster, RH ;
Curtis, BR ;
Bougie, DW ;
Dunkley, S ;
Greinacher, A ;
Warkentin, TE ;
Chong, BH .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2006, 4 (03) :678-679
[2]  
Bazzino O, 1998, NEW ENGL J MED, V338, P1498
[3]  
Bazzino O, 1998, NEW ENGL J MED, V338, P1488
[4]   Evidence that thrombocytopenia observed in humans treated with orally bioavailable glycoprotein IIb/IIIa antagonists is immune mediated [J].
Billheimer, JT ;
Dicker, IB ;
Wynn, R ;
Bradley, JD ;
Cromley, DA ;
Godonis, HE ;
Grimminger, LC ;
He, BK ;
Kieras, CJ ;
Pedicord, DL ;
Spitz, SM ;
Thomas, BE ;
Zolotarjova, NI ;
Gorko, MA ;
Hollis, GF ;
Daly, RN ;
Stern, AM ;
Seiffert, D .
BLOOD, 2002, 99 (10) :3540-3546
[5]   Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIa [J].
Bougie, DW ;
Wilker, PR ;
Wuitschick, ED ;
Curtis, BR ;
Malik, M ;
Levine, S ;
Lind, RN ;
Pereira, J ;
Aster, RH .
BLOOD, 2002, 100 (06) :2071-2076
[6]   Delayed thrombocytopenia after treatment with abciximab: a distinct clinical entity associated with the immune response to the drug [J].
Curtis, BR ;
Divgi, A ;
Garritty, M ;
Aster, RH .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2004, 2 (06) :985-992
[7]   Thrombocytopenia after second exposure to abciximab is caused by antibodies that recognize abciximab-coated platelets [J].
Curtis, BR ;
Swyers, J ;
Divgi, A ;
McFarland, JG ;
Aster, RH .
BLOOD, 2002, 99 (06) :2054-2059
[8]   Profound thrombocytopenia induced by clopidogrel with a prior history of long-term safe administration [J].
Guo, Yuan-Lin ;
Li, Jian-Jun ;
Yuan, Jin-Qing ;
Qin, Xue-Wen ;
Zheng, Xin ;
Mu, Chao-Wei ;
Hua, Yi-Hong .
WORLD JOURNAL OF CARDIOLOGY, 2010, 2 (06) :160-162
[9]  
Hanrath P, 1997, CIRCULATION, V96, P1445
[10]   Frequency and management of thrombocytopenia with the glycoprotein IIb/IIIa receptor antagonists [J].
Huxtable, LM ;
Tafreshi, MJ ;
Rakkar, ANS .
AMERICAN JOURNAL OF CARDIOLOGY, 2006, 97 (03) :426-429